{
    "clinical_study": {
        "@rank": "48611", 
        "acronym": "LX1606-104", 
        "arm_group": {
            "arm_group_label": "500 mg LX606", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will receive a single oral 500 mg dose of [14C]-LX1606."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and\n      its primary metabolite LX1033."
        }, 
        "brief_title": "An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males", 
        "condition": "Carcinoid Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoid Tumor", 
                "Malignant Carcinoid Syndrome", 
                "Serotonin Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects aged 30 to 65 years of age.\n\n          -  Male subjects and their partners must agree to use an adequate method of\n             contraception\n\n          -  Historically able to produce a minimum of 1 bowel movement every day on most days\n\n        Exclusion Criteria:\n\n          -  Female subjects\n\n          -  Use of any medication or supplement within 5 days prior to Dosing\n\n          -  Radiation exposure exceeding 5 millisieverts (mSv) in the last 12 months or 10 mSv in\n             the last 5 years\n\n          -  Current smokers or the use of cigarettes within 90 days prior to Screening\n\n          -  History or renal disease or abnormal kidney function\n\n          -  History of hepatic disease\n\n          -  Acute diarrhea or constipation within 7 days of dosing\n\n          -  Positive urine glucose at Screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932528", 
            "org_study_id": "LX1606.1-104-NRM"
        }, 
        "intervention": {
            "arm_group_label": "500 mg LX606", 
            "description": "500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as [14C]-LX1606.", 
            "intervention_name": "500 mg [14C]-LX1606", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Absorption", 
            "Metabolism", 
            "Excretion"
        ], 
        "lastchanged_date": "October 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Lexicon Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Doug Fleming, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Maximum plasma concentration of LX1606 and LX1033", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932528"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to maximum plasma concentration of  and LX1033", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Determination of total radioactivity in blood and plasma", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Mass balance recovery of total radioactivity in urine and feces", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Metabolite profiling and identification in plasma", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Metabolic profiling and identification in urine", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Metabolic profiling and identification in feces", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}